Tong Ren Tang Technologies Co (1666) Fair Value & Analysis
Healthcare · HK · Market cap HK$4.1B
Fair value as of: Jul 5, 2026
From 26 valuation models · updated today
Fair value updated Jul 5, 2026 — revised from HK$16.01 to HK$8.16 (−49.0%) since Jul 2, 2026. Share price +0.2% over the past month.
Price vs Fair Value (12 months)
12‑month range HK$3.13 – HK$5.09 · fair‑value band HK$6.12 – HK$10.20 · the HK$3.34 price screens below the HK$8.16 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Tong Ren Tang Technologies Co (1666) currently trades at HK$3.34, while our model-based Fair Value estimate is HK$8.16 — implying the stock looks roughly 144.3% undervalued today. We read business quality at 59/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, Tong Ren Tang Technologies Co generated revenue of HK$6.5B at a net margin of 6.1%. Revenue declined 14.5% year over year. It earns a return on equity of 6.5%. The balance sheet holds a net cash position of HK$2.5B. Fundamentals as of Jul 5, 2026
Our scenario range runs from HK$6.12 (bear case) to HK$10.20 (bull case); at HK$3.34, the current price sits below that range. The share trades about 36% below its 52-week high and 9% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -42% fair-value upside — at 144%, 1666 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Tong Ren Tang Technologies Co. Ltd., together with its subsidiaries, produces and distributes Chinese medicine products in Mainland China and Hong Kong. It operates through three segments: The Company; Tong Ren Tang Chinese Medicine; and Others. The company develops, cultivates, processes, and purchases Chinese medicinal raw materials; retails and wholesales Chinese medicine products and healthcare products. It also offers ointments, healthcare products, tea drinks, food, foot care products, biological products, western medicine, and cosmetics. In addition, it provides medical research and development; advertisement; and Chinese medical consultations and treatments. Further, the company produces and processes biochemical products; extracts and processes plants; and offers medical services. Tong Ren Tang Technologies Co. Ltd. was founded in 1669 and is based in Beijing, the People's Republic of China.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Tong Ren Tang Technologies Co reported revenue of HK$6.5B in FY2025 versus HK$5.4B in FY2021, a compound +4.7%/yr. Reported net income was HK$396M in FY2025, compounding −6.0%/yr from FY2021.
Is 1666 fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,136 | $630.79 | -44% |
| Johnson & Johnson, JNJ | 4,128 MXN | 2,401 MXN | -42% |
| AbbVie Inc ABBV | $230.01 | $133.86 | -42% |
| Roche Holding ROGN | 7,050 MXN | 316.37 MXN | -96% |
| Merck & Co MRCK34 | R$76.74 | R$50.09 | -35% |
| AstraZeneca PLC A1ZN34 | R$159.89 | R$87.02 | -46% |
| Novartis AG N1VS34 | R$76.31 | R$12.63 | -83% |
| Novo Nordisk A/S, NOVOB | kr 299.95 | kr 542.67 | +81% |
| Amgen Inc AMGN | 6,170 MXN | 253.17 MXN | -96% |
| Gilead Sciences, Inc GIS | €108.32 | €204.69 | +89% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Tong Ren Tang Technologies Co (1666) undervalued?
What is the fair value of 1666?
What is the quality score of 1666?
What is the revenue of Tong Ren Tang Technologies Co (1666)?
What is the net profit margin of 1666?
Does Tong Ren Tang Technologies Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.